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Background: Hepatitis B virus (HBV) infection is a major global health problem. The infectious virion contains an
inner “core particle”, which is made of 180 or 240 copies of core protein, alternatively known as hepatitis B core
antigen, or HBcAg which encloses the viral genome.
Method: In this study, we characterized HBV genotypes and used Bayesian analyses to estimate date of emergence
of the most recent common ancestor (TMRCA) of three HBV genotypes, A, B, and D.
Results: We estimated that the rate of evolution of HBV core protein gene to be 1.127 (0.925–1.329, 95% HPD)
substitutions per site per year. The TMRCA of HBV for genotypes A, B, D were 118 (54–194, 95% HPD) year, 184
(78–323, 95% HPD) year and 133 (65–230, 95% HPD) year, respectively. Demographic histories of the HBcAg gene
showed that the relative genetic diversity had a sharp increase within the first 10 years of its emergence.
Conclusion: Using a bayesian evolutionary method to predict the outbreak trends of HBV through evolutionary
trees of HBV, and provide theoretical foundations for clinical prevention and treatment of HBV.
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HBV is a genus of DNA viruses which infects the humans
causing acute and chronic hepatitis [1]. The World Health
Organization estimates that more than 2 billion people
have been infected with the hepatitis B virus [2], of which
there are 350 million chronic carriers [3]. In recent years,
there have been many studies on HBV genotypes and their
clinical relationships. It has been shown that HBV
genotypes reflect the natural heterogeneity between virus
strains more accurately than serotypes.
There are ten different HBV genotypes (A-J) whose
prevalences are variably distributed geographically [4].
Genotype A is common in sub-Saharan Africa, Northern
Europe and West Africa. Genotypes B and C are highly* Correspondence: 466634002@qq.com; qing@jlu.edu.cn
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reproduction in any medium, provided the orprevalent in Asia. Genotypes D is highly prevalent in Asia
and Africa, and D1 in North Africa, Europe, Central Asia,
D2 in North Europe, Russia, Japan (Ehime), D3 in South
Africa, Europe, D4 in Australia, D5 in East India [5,6].
Genotype E has been reported in West Africa. Genotype F
is found in Central and South America, while genotype G
is found in France, Germany and the United States. The
eighth genotype, H, has been reported to be present in
Central America [7]. At present, genotype I has been de-
scribed in Vietnam and Laos [8,9]. The newest HBV geno-
type, J, was identified in the Ryukyu Islands in Japan, and
this genotype has a close relationship with gibbon/orangu-
tan genotypes, and human genotype C [10]. There are
many applications behind the study of genotypes in HBV.
These include elucidation of novel mechanisms of disease
pathogenesis, development of biomarkers for disease
prognosis or treatment outcome, and identification of po-
tential therapeutic targets. At the same time, there were
many people have reported the evolutionary analysis of
HBV by different regions of genes and genomes [11,12].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 The maximum clade credibility (MCC) tree was estimated using Bayesian analysis with HBcAg gene sequences about ~660 bp
of HBV. The key nodes above the respective nodes were used to show the posterior probabilities. The green color depict genotype D (n = 54),
and blue pink color display genotype A (n = 55) and B (n = 44).
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http://www.virologyj.com/content/10/1/256HBV is characterized by high rates of replication (1012-13
virions/day), and high rates of mutation (1010-11 point mu-
tation/day) which increase the likelihood of the appearance
of conserved changes which ultimately can lead to the
emergence of new genotypes. The various HBV genotypes
are associated with differences in pathogenicity [5], disease
progression [13] and responses to antiviral drugs [14].
In this article, we carried out genotype classification of
HBV according to the HBcAg (core) gene by the Bayesian
method to estimate date of emergence of the most recent
common ancestor (TMRCA) of three common HBV ge-
notypes. We predicted the outbreak trends of HBV
through evolutionary trees of HBV, and provide theoretical
foundations for clinical prevention and treatment of HBV.
Material and methods
Sequence collection
A total of 580 HBcAg gene sequences from GenBank were
downloaded (www.ncbi.nlm.nih.gov), of which 153 hadTable 1 Estimates of the relative substitution rates for
the core gene of all three codon positions
Summary statistic CP1.mu CP2.mu CP3.mu
Mean 0.506 1.539 0.953
95% HPD lower 0.448 1.458 0.881
95% HPD upper 0.567 1.618 1.030
Effective sample size (ESS) 12715 8705 5650known collection dates, genotype and isolate, and country
of origin. Samples obtained between 1990 and 2012 were
retrieved for analysis (the accession numbers of these se-
quences are available through biowcg@yahoo.com). These
sequences were processed using BioPerl to generate the
format required for manipulation by BEAST 1.6 [15]. Se-
quences were aligned using MEGA5 software [16], and
edited with the SEAL software (available at http://tree.bio.
ed.ac.uk/software/seal/). Any missing nucleotides were
coded as “missing characters” in the nexus block because
BEAST cannot perform the alignments.
Genotyping analysis
Using the HBV genotype data, the strains were col-
lected using the Markov Chain Monte Carlo method.
MCMC together with the information on collection
dates, using Bayesian analyses were performed to esti-
mate the time emergence of the most recent common
ancestor (TMRCA) [17]. This information led us to
make inferences about the oldest, and also the youngest
HBV genotypes. The results were summarized using
the program TreeAnnotator 1.6.1, and the maximum
clade credibility (MCC) tree was constructed. FigTree
was used to display the tree.
Bayesian MCMC evolutionary analyses
After the TMRCA was done with BEAST 1.6, convergence
was inspected using Tracer v1.6, with uncertainties
Figure 2 Marginal density of relative substitution rate densities for all three codon positions of the HBcAg gene.
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using the Hasegawa-Kishino-Yano (HKY) nucleotide sub-
stitution models, with a gamma-distributed among-site
rate variation with four rate categories [18]. We did the
Bayesian MCMC analysis for 50 million states, and sam-
pled every 50,000 states. We set a burn-in of 2 million
states for the posterior probabilities, and then showed
the results using Tracer, version 1.6. We used Bayesian
skyline plots to show the relative viral genetic diversity
for HBV core protein gene [19].About tMRCA
The most recent common ancestor (MRCA) of any set
of organisms is the most recent individual from which
all organisms in the group are directly descended.
Such time to MRCA (TMRCA) estimates can be given
based on DNA test results and established mutation
rates as practiced in genetic genealogy, or by referenceTable 2 Evolutionary characteristics of HBV genotypes base






TMRCA (B) Japan,1988 [20]
TMRCA (D) Japan,1988 [20]




The most common HBV genotype is C, followed by B.
However, most of the available data are on genotypes
A, B and D. Therefore, we undertook to study the evo-
lution of HBV by analyzing these three genotypes. A
total of 580 HBcAg gene sequences were downloaded
from GenBank (www.ncbi.nlm.nih.gov), of which 153
sequences had collection dates between 1990 and 2012.
These were used for molecular characterization. We es-
timated the maximum clade credibility (MCC) tree
using a Bayesian analysis of core protein (C) gene se-
quences with ~660 bp of hepatitis B virus strains. The
results are shown in Figure 1. The phylogeny showed
that (1) (A/B/D) genotypes were clustered together.
The blue color depicts genotype A (n = 55), and pinkd on the HBcAg gene using the uncorrelated log normal
HBV TMRCA (years; 95% HPD) Emergence




Figure 3 Marginal density of TMRCA for various HBV genotypes based on the HBcAg gene using an models of exponential population
growth and a relaxed molecular clock, which were prepared by BEAST v1.6.1.
Time





Figure 4 The genetic diversity dynamics of HBV tree model, root height. We can see that the plot for the HBcAg gene has a sharp rise in
1810 which for the relative genetic diversity.
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http://www.virologyj.com/content/10/1/256and green color display, genotypes D (n = 54) and B
(n = 44), respectively; (2) genotypes A and D appeared
to have a closer evolutional relationship than genotype
B. However, they branched laterally from genotype B at
an earlier time point; (3) genotype D also has subtypes.
The various genotypes of HBV have differences in
terms of levels of replication, and expression of viral
markers. In addition, natural variations of HBV may
occur in the process of the infection in the host. The
accumulation of these variations can result in large
changes in genomic nucleotide sequences of HBV, and
eventually in the appearance of new genotypes.
Evolutionary rate, TMRCA of each HBV genotype we
collected
To understand the evolution of HBV, we estimated mo-
lecular clock phylogenies, evolution rates, and divergence
times using the Bayesian MCMC method. All three codon
positions of the HBcAg gene had different relative substi-
tution rates (Table 1 and Figure 2). The mean values of
the first, second, and third codon positions were 0.506,
1.539 and 0.953, respectively. Among these codon posi-
tions, the relative substitution rates of the second and the
third codons were all greater than 1. Because the variance
ratio was comparatively large, there was high variability
and a high outbreak rate of HBV. At the same time, our
analysis showed that the HBcAg gene evolutionary rate
was estimated to be 1.127E-3 substitutions/site/year
(Table 2 and Figure 3). The TMRCA of genotypes A, B
and D of HBV were 118, 184 and 133, respectively so their
corresponding emergence dates were calculated to be
1894, 1828 and 1879. Table 2 summarizes the dates of ini-
tial reports for each genotype included in our analysis.
Someone used to calculate the evolutionary rates of HBV
by the method of Bayesian algorithm and had found some
specific evolutionary areas, these areas may have some-
thing to do with the high mutation rates of HBV [11]. The
evolution of HBV was also be studied by the gene of
HBsAg, its findings showed that HBV has always had high
mutation rate in history [12]. Our study used different
from these two papers. The first one used 108 HBV ge-
nomes. They indeed used more genomes in other geno-
types except D. We actually download all HBV genomes
and HBcAg region sequences and removed the genomes
without region annotation. The second paper used HBsAg
gene to do the analysis.
Dynamics of population growth
Bayesian skyline plot analyses was used to investigate
the dynamics of HBcAg gene genetic diversity over time
(Figure 4), by which changes in genetic diversity can be
observed as a function of time. There was a very sharp
increase in relative genetic diversity (g) for the HBcAg
gene in the first 10 years from 1810. The same tendencywas observed for genotypes A, B, D according the max-
imum clade credibility (MCC) tree as shown in Figure 1.
The current study shows that the mutation rates for
genotype A/B are much higher than that for genotype D.
The reason for this may be that the populations included
in these studies were mainly European and American, in
which genotype A is predominant. in contrast to the
situation in Eastern Asia where B genotype is predomin-
ant. In Europe and America, hepatitis B immune globu-
lin (HBIG) is routinely used to block maternal-neonatal
transmission [21], prevent HBV re-infection after liver
transplantation [22], as well as to prevent infection after
known acute exposures [23]. The observed increase in
mutation rates could have been due to the effects of
antiviral treatment [24], inoculation of hepatitis B vac-
cine or hepatitis B immune globulin [25].
Because the various genotypes of HBV exhibit differ-
ent pathogenic features, and responses to drug treat-
ment, the study of HBV genotypes has important clinical
implications. HBV genotypes (1) can be useful for stud-
ies on epidemiology and regional distribution, pathogen-
icity and genetic variations, as well as emergence of
mutational strains in various populations; (2) can suggest
routes of transmission. For example, genotype A has
been associated with sexual contact, while genotype D
has been associated with blood transmission [14]; (3) the
effectiveness of vaccines, particularly with regard to the
relationship between genotype and maternal-neonatal
transmission; (4) the relationship between genotypes and
antiviral efficacy.Conclusions
We predicted the dynamic phylogenetic trends, which in-
dicate outbreak trends of HBV, and provide theoretical
foundations for clinical prevention and treatment of HBV.
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